CYP11B2 and neoplasm: The high percentage of uptake-negative lesions was attributed to a limited ability to detect small lesions (≤2–3 cm), with tumour necrosis or de-differentiation of tumour clones (such that lesions express less CYP11B enzyme—either in progressive tumours or in response to medical treatment), also potentially contributory.